Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2024-194601

Published: 2024

Journal Articles

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Blood (2024) 144 (Supplement 1): 5099.

https://doi.org/10.1182/blood-2024-198742

Published: 2024

Journal Articles

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Nina Wagner-Johnston, Opeyemi Jegede, Stephen E Spurgeon, Kami J. Maddocks, David T Yang, Justin Romanoff, Jonas Paludo, Paolo F. Caimi, Nancy L. Bartlett, Patrick M. Reagan, Yazeed Sawalha, Marc Hoffmann, Boyu Hu, Ashraf R Aziz, Helga Marques, Lale Kosakoglu Shields, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl

Blood (2024) 144 (Supplement 1): 236.

https://doi.org/10.1182/blood-2024-194641

Published: 2024

Journal Articles

Final Update of Safety, Efficacy and T-Cell Predictive Biomarkers from a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey Shouse, Leslie Popplewell, Alex Muir, Tanya Siddiqi, Jasmine Zain, Alex F. Herrera, Olga Danilova, Stephen E Spurgeon, Lili Wang, Adam S Kittai, Lu Chen, Matthew S. Davids, Alexey V. Danilov

Blood (2024) 144 (Supplement 1): 4484.

https://doi.org/10.1182/blood-2024-209610

Published: 2024

Journal Articles

A Phase II Study of Intermittent Duvelisib Dosing in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Geoffrey P. Shouse, Lu Chen, Tanya Siddiqi, Alex Muir, Jennifer R. Brown, Stephen E Spurgeon, Alexey Danilov

Blood (2023) 142 (Supplement 1): 6531.

https://doi.org/10.1182/blood-2023-182543

Published: 2023

Journal Articles

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Blood (2023) 142 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2023-173992

Published: 2023

Journal Articles

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 497.

https://doi.org/10.1182/blood-2023-182114

Published: 2023

Journal Articles

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Stephen E. Spurgeon, Matthew Mei, Paul M. Barr, Jacqueline C. Barrientos, Sven de Vos, Richard R. Furman, Krish Patel, Philip A. Thompson, Michael Y. Choi, Avyakta Kallam, Sirou Wang, Uzor C. Ogbu, Akash Nahar, Michael L. Wang

Blood (2022) 140 (Supplement 1): 6640–6641.

https://doi.org/10.1182/blood-2022-163509

Published: 2022

Journal Articles

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Victor Manuel Orellana-Noia, Daniel R. Reed, Ashley Alesia McCook, Jeremy Michael Sen, Christian M. Barlow, Mary-Kate Malecek, Marcus Watkins, Brad S. Kahl, Michael A. Spinner, Ranjana Advani, Timothy J. Voorhees, Anson Snow, Natalie Sophia Grover, Amy Ayers, Jason Romancik, Yuxin Liu, Scott F. Huntington, Julio C. Chavez, Hayder Saeed, Aleksandr Lazaryan, Vikram Raghunathan, Stephen E. Spurgeon, Thomas A. Ollila, Christopher Del Prete, Adam Olszewski, Emily C. Ayers, Daniel J. Landsburg, Benjamin Echalier, Jun Lee, Manali Kamdar, Paolo F. Caimi, Timothy Fu, Jieqi Liu, Kevin A. David, Hanan Alharthy, Jennie Law, Reem Karmali, Harsh Shah, Deborah M. Stephens, Ajay Major, Alexandra E. Rojek, Sonali M. Smith, Amulya Yellala, Avyakta Kallam, Shazi Nakhoda, Nadia Khan, Mohammad Ahsan Sohail, Brian T. Hill, Odeth Barrett-Campbell, Frederick Lansigan, Jeffrey Switchenko, Jonathon Cohen, Craig A. Portell

Blood (2022) 139 (3): 413–423.

https://doi.org/10.1182/blood.2021012888

Published: 2022

Includes: Supplemental data

Journal Articles

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Michael Wang, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip A. Thompson, Michael Choi, Avyakta Kallam, Ying Zhu, Samhita Chakraborty, Patricia Marinello, Stephen E. Spurgeon

Blood (2021) 138 (Supplement 1): 528.

https://doi.org/10.1182/blood-2021-148607

Published: 2021

Journal Articles

Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Alexey V. Danilov, Vi Lam, Bria Thurlow, Stephen E. Spurgeon, Byung Park, Kirsten Orand, Adam S Kittai

Blood (2021) 138 (Supplement 1): 2643.

https://doi.org/10.1182/blood-2021-146348

Published: 2021

Journal Articles

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-136373

Published: 2020

Journal Articles

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Prashasti Agrawal, Kevin A. David, MD, Zhengming Chen, PhD MPH, MS, Suchitra Sundaram, MD, Seo-Hyun Kim, MD, Ryan Vaca, MD, Yong Lin, PhD, Samuel Singer, MD, Mary-Kate Malecek, MD, Jordan Carter, MD, Adam Zayac, MD, Myung Sun Kim, MD, Nishitha Reddy, MD, Alma Habib, MD, Christopher Strouse, MD, Jerome Graber, MD, Veronika Bachanova, MD PhD, Mazie Tsang, MD, Ajay Major, MDMBA, David A. Bond, MD, Angel Mier-Hicks, MD, Pallawi Torka, MD, Priya Rajakumar, MD, Parameswaran Venugopal, MD, Michael Glantz, MD PhD, Samuel Goldlust, MD, Rahul Matnani, MD, Pallavi Kumar, MD, Thomas A Ollila, MD, Johnny Cai, DO, Stephen E. Spurgeon, MD, Alex G Sieg, MD MS, Joseph Cleveland, MD, Narendranath Epperla, MDMS, Reem Karmali, MDMSc, Seema Naik, MD, Sonali M. Smith, MD, James L. Rubenstein, MD PhD, Brad S. Kahl, MD, Amy Chadburn, MD, Andrew M. Evens, DO,MMSc, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 4–6.

https://doi.org/10.1182/blood-2020-138885

Published: 2020

Journal Articles

CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Victor M. Orellana-Noia, MD, Daniel R Reed, MD, Jeremy M Sen, PharmD, BCOP, Christian Barlow, MD, Mary-Kate Malecek, MD, Brad S. Kahl, MD, Michael A Spinner, MD, Ranjana Advani, MD, Timothy J Voorhees, MD, Anson Snow, MD, Natalie S Grover, MD, Amy Ayers, MPH, Jason T. Romancik, MD, Yuxin Liu, MD, Scott F. Huntington, MD MPH, Julio C. Chavez, MD, Hayder Saeed, MD, Aleksandr Lazaryan, MDPhDMPH, Vikram Raghunathan, MD, Stephen E. Spurgeon, MD, Thomas A Ollila, MD, Christopher Del Prete, MD, Adam J Olszewski, MD, Emily C. Ayers, MD, Daniel J. Landsburg, MD, Benjamin Echalier, Jun Lee, Manali Kamdar, MD, Paolo F Caimi, MD, Timothy Fu, MD, Jieqi Liu, MD, Kevin A. David, MD, Hanan Alharthy, MD, Jennie Y. Law, MD, Reem Karmali, MDMSc, Harsh Shah, DO, Deborah M. Stephens, DO, Ajay Major, MDMBA, Alexandra E Rojek, MD, Sonali M. Smith, MD, Amulya Yellala, MBBS, Avyakta Kallam, MD, Shazia Nakhoda, MD, Nadia Khan, MD, Jonathon B. Cohen, MDMS, Craig A. Portell, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-134798

Published: 2020

Journal Articles

Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-136551

Published: 2020

Journal Articles

SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Adam S. Kittai, MD, Scott R Best, BS, Bria Thurlow, BSc, Basak Gokcora, Andrzej Stadnik, MPH, BS, Renee MacKinnon, Taylor Hashiguchi Rowland, BS, Daniel O. Persky, MD, Byung Park, PhD, Stephen E Spurgeon, MD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4295.

https://doi.org/10.1182/blood-2019-123586

Published: 2019

Journal Articles

Immunomodulatory Effects of Pevonedistat, a NEDD8-Activating Enzyme (NAE) Inhibitor, in Chronic Lymphocytic Leukemia (CLL)

Scott R Best, BS, Adam Kittai, MD, Taylor Rowland, BS, Nur Bruss, BS, Stephen E Spurgeon, MD, Allison Berger, PhD, Amy Moran, PhD, Alexey V Danilov, MD PhD

Blood (2018) 132 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2018-99-115086

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Franck Morschhauser, MD, John Radford, MD FRCP, Loic Ysebaert, MD PhD, Stephen E Spurgeon, MD, Ebenezer A Kio, MD, Gilles Salles, MD PhD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 5345.

https://doi.org/10.1182/blood-2018-99-113117

Published: 2018

Journal Articles

TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in CLL Cells

Scott R Best, BS, Taylor Rowland, BS, Cody Paiva, BS, Nur Bruss, BS, Stephen E Spurgeon, MD, Allison Berger, PhD, Alexey V Danilov, MD PhD

Blood (2018) 132 (Supplement 1): 1867.

https://doi.org/10.1182/blood-2018-99-114964

Published: 2018

Journal Articles

Medical Comorbidities Assessed By CIRS Negatively Impact Survival in the Era of Targeted Therapies in CLL: A Multicenter Retrospective Analysis

Max J Gordon, MD, Stephen M Amrock, SM, MD, Xavier Issac Rivera, BS, Spencer James, MD, Sudhir Manda, MD, Stephen E Spurgeon, MD, Daniel Persky, MD, Alexey Danilov, MD PhD

Blood (2017) 130 (Supplement 1): 918.

https://doi.org/10.1182/blood.V130.Suppl_1.918.918

Published: 2017

NARROW

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Final Update of Safety, Efficacy and T-Cell Predictive Biomarkers from a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

A Phase II Study of Intermittent Duvelisib Dosing in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Immunomodulatory Effects of Pevonedistat, a NEDD8-Activating Enzyme (NAE) Inhibitor, in Chronic Lymphocytic Leukemia (CLL)

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in CLL Cells

Medical Comorbidities Assessed By CIRS Negatively Impact Survival in the Era of Targeted Therapies in CLL: A Multicenter Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only